The phase II ROME trial demonstrated that personalized therapy guided by combined tissue and liquid biopsies significantly ...

Researchers from Karolinska Institutet developed a non-invasive urine test for early prostate cancer detection, utilizing AI, ...

Bayer has launched a first-in-human clinical trial for 225Ac-GPC3 (BAY 3547926), a novel targeted alpha radiopharmaceutical ...

The first AI-powered companion diagnostic for non-small cell lung cancer has received FDA Breakthrough Device Designation.

Merck has launched construction of a $1 billion biologics facility in Wilmington, set to become the U.S. production hub for ...

Microbiotica’s MB097, an oral microbiome-based therapy, shows promise in boosting immunotherapy response in melanoma patients ...

The US FDA has cleared the investigational new drug (IND) application to begin clinical trials for BFB-101, a novel gene ...

Boehringer Ingelheim has announced a collaboration with Tessellate Bio, to develop a new class of targeted therapies for ...

In the phase 3 HARMONi-6 trial, ivonescimab (SMT112), Akeso’s PD-1/VEGF bispecific antibody, combined with chemotherapy, demonstrated statistically significant and clinically meaningful improvement in ...